Collaborations & Alliances, Trials & Filings

Pfizer, GSK Collaborate on Melanoma

Will combine GSK's Mekinist with Pfizer's investigational palbociclib

By: Gil Roth

President, Pharma & Biopharma Outsourcing Association

Pfizer and GSK have entered into an agreement to explore the anti-cancer efficacy and the safety of GSK’s trametinib (GSK1120212) combined with Pfizer’s palbociclib (PD-0332991) in a Phase I/II study (Study 200344) in patients with advanced/metastatic melanoma. The study is a dose-escalation, open-label study designed to determine the recommended combination regimen (RCR) for trametinib plus palbociclib in patients with melanoma. The study will also evaluate the effect of the combination on tum...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters